Antihypertensive and antithrombotic activities of a commercial fermented milk product made with Lactobacillus casei Shirota and Streptococcus thermophilus

10Citations
Citations of this article
22Readers
Mendeley users who have this article in their library.
Get full text

Abstract

Peptides which inhibit the human angiotensin-converting enzyme (ACE) may be released during milk fermentation, and the micro-organisms or fermentation conditions influence the specific peptides produced. The aim of this study was to evaluate the ACE inhibitory and antithrombotic activities of a fermented milk product commercially available in Mexico. Viable cell numbers, protein hydrolysis and the pH remained constant during refrigerated storage. The IC50 of ACE inhibitory activity was 31.38 mg/mL. Eight peptide fractions exhibited ACE inhibitory activity and six showed antithrombotic activity. Two fractions showed both. This is the first time that both activities have been reported in a commercial probiotic product. © 2014 Society of Dairy Technology.

Cite

CITATION STYLE

APA

Domínguez-González, K. N., Cruz-Guerrero, A., González-Márquez, H., Gómez-Ruiz, L., García-Garibay, M., Jiménez-Guzmán, J., & Rodríguez-Serrano, G. (2014). Antihypertensive and antithrombotic activities of a commercial fermented milk product made with Lactobacillus casei Shirota and Streptococcus thermophilus. International Journal of Dairy Technology, 67(3), 358–364. https://doi.org/10.1111/1471-0307.12133

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free